

27. (New) The method of Claim 26 wherein the dose units are in the form of discrete solid articles.
28. (New) The method of Claim 27 wherein the solid articles are tablets or capsules
29. (New) The method of Claim 25 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.
30. (New) The method of Claim 25 wherein the five- to six-membered ring is selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
31. (New) The method of Claim 25 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

Remarks

This paper cancels Claims 1, 3, 8-11 and 16-18 without prejudice or disclaimer, amends claims 2, 4, 6, 12 and 13; and submits new claims 19-31. Claims 2, 4-7, 12, 13 and 19-31 are pending in the case.

No new matter is believed to be added by the above amendments to the claims. Amended Claim 2 finds support in Claim 2 as originally filed; on page 11, lines 7-8; in Example 1, Table 1 and in Claim 11 as originally filed.

Claim 19 is supported by Claim 16 as originally filed, on page 11, lines 7-8; in Example 1, Table 1 and in Claim 11 as originally filed.

Claim 20 is support by Claim 17 as originally filed.

Claim 21 is supported by Claims 16 and 4 as originally filed.

Claim 22 is supported by Claims 16 and 5 as originally filed.

Claim 23 is supported by Claims 16 and 6 as originally filed.

Claim 24 is supported by Claims 16 and 12 as originally filed.

Claim 25 is supported by Claims 16 and 13 as originally filed.

Claim 26 is supported by Claim 18 as originally filed; on page 11, lines 7-8; in Example 1, Table 1; and by Claim 11 as originally filed.

Claim 27 is supported by Claims 18 and 4 as originally filed.

Claim 28 is supported by Claims 18 and 5 as originally filed.


Claim 29 is supported by Claims 18 and 6 as originally filed.

Claim 30 is supported by Claims 18 and 12 as originally filed.

Claim 31 is supported by Claims 18 and 13 as originally filed.

It is requested that the amendments above be entered and that the claims be examined on the merits. Should any questions arise, the Patent and Trademark Office is requested to contact the undersigned attorney.


Respectfully submitted,



Donald R. Holland Reg. No. 35197
HARNESS, DICKEY & PIERCE, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500

AMENDED CLAIMS IN MARKED UP VERSION

2. (Amended) A pharmaceutical composition comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a [D₉₀ particle size of about 0.01 μm to about 200 μm, and wherein about 25% to 100% by weight of the particles are smaller than 1 μm] weight average particle size of about 500 nm to about 900 nm, and wherein the selective cyclooxygenase-2 inhibitory drug is a compound of formula



- where R³ is a methyl or amino group, R⁴ is hydrogen or a C₁₋₄ alkyl or alkoxy group, X is N or CR⁵ where R⁵ is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups.
4. (Amended) The composition of [any of Claims] Claim 1 [to 3] wherein the dose units are in the form of discrete solid articles.
6. (Amended) The composition of [any of Claims] Claim 1 [to 3] that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.
12. (Amended) The composition of Claim [11] 1 wherein the five- to six-membered ring is selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.

13. (Amended) The composition of [any of Claims] Claim 1 [to 10] wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.